Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended 30th June, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting - Un-Audited Financial Results (Standalone and Consolidated)
Date of Board Meeting / Approval: August 6, 2026 (11:30 AM to 12:30 PM IST)
Audit Opinion: Unmodified review reports from statutory auditors
Auditor's Comment: No qualifications or modifications; nothing came to their attention to suggest material misstatement
Key Financial Highlights [Rs. in Lakhs]
Standalone Results:
Revenue from Operations: ₹356.58 (Q1 FY27) vs ₹186.67 (Q1 FY26) - 91% YoY increase
Total Income: ₹1,108.94 (Q1 FY27) vs ₹245.57 (Q1 FY26)
Net Profit/(Loss): (₹1,611.91) (Q1 FY27) vs (₹1,477.87) (Q1 FY26) - Loss widened by 9.1% YoY
EPS: (₹0.61) basic and diluted (not annualized)
Other Equity: Not specified for quarter; ₹147,699.51 for year ended March 31, 2026
Cash and Cash Equivalents: Not disclosed
Debt: Finance costs of ₹47.61 lakhs reported
Consolidated Results:
The consolidated financial results include the results of the wholly owned subsidiary, Suven Neurosciences, Inc.
The subsidiary reflected total revenues Nil, and total net loss after tax of ₹(11,149.11) lakhs for the quarter
Financial Performance Analysis:
Total expenses increased to ₹2,720.85 lakhs (Q1 FY27) from ₹1,723.44 lakhs (Q1 FY26)
Employee benefits expense: ₹728.18 lakhs (Q1 FY27) vs ₹597.56 lakhs (Q1 FY26)
R&D Expenses: ₹1,275.60 lakhs (Q1 FY27) vs ₹518.77 lakhs (Q1 FY26) - 146% increase YoY
Depreciation and amortisation: ₹215.51 lakhs (Q1 FY27) vs ₹136.84 lakhs (Q1 FY26)
Other Expenses: ₹453.95 lakhs (Q1 FY27) vs ₹470.27 lakhs (Q1 FY26)
Segment-wise Performance:
The Company has only one business segment: Research & Development
No segment reporting presented as per IND AS 108
Corporate Actions:
ESOP Scheme:
- 1,33,200 stock options granted on May 13, 2026 under SLSL Employee Stock Option Scheme 2020
- Employee benefit expense of ₹145.54 lakhs recognized for the quarter
- 2,71,970 equity shares of ₹1 each allotted during the quarter pursuant to exercise of stock options
Preferential Issue:
- Board approved issue of 6,40,02,999 convertible warrants to 23 allottees on preferential basis (approved May 13, 2025)
- Shareholders approved on June 5, 2025
- Each warrant convertible into one equity share at exercise price of ₹134 per share within 18 months from allotment
- As of June 30, 2026: Entire amount of ₹85,764.02 lakhs received from warrant holders
- During Q1 FY27: Received ₹9,331.49 lakhs for 1,85,70,133 warrants (allotment pending)
- Amount utilized: ₹40,950.29 lakhs
- Balance amount: ₹44,813.73 lakhs
Other Significant Information:
Clinical Development Pipeline:
- SUVN-502 (Masupirdine): Achieved 95% enrollment in Global Phase 3 Trial for Agitation in Alzheimer's Dementia. Completion of enrollment expected by end September 2026; last patient last visit in Q1 2027; results potentially in Q2 2027
- SUVN-G3031 (Samelisant): Global Phase 3 clinical trial initiated for treatment of EDS in Narcolepsy in April 2026
- SUVN-911 (Ropanicant): Successfully completed Phase 2b clinical trial for Major Depressive Disorder (MDD)
- SUVN-D4010 (Usmarapride): Phase 2 PoC study design being finalized for cognitive impairment in psychiatric disorder
- SUVN-I6107: Phase 1 study completed; preparing for Phase 2 clinical study
Business Description:
Suven is a Biopharmaceutical company engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.